“Genotype-Related Efficacy and Adverse Effects of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder” (2022) Precision Medicine Communications, 2(1), pp. 27–42. doi:10.55627/pmc.002.01.0044.